AbbVie will offer Humira on the White House’s TrumpRx direct-to-consumer platform at a reported $950-per-month price, as the administration pairs discounted biosimilars with a tariff-avoidance strategy. The TrumpRx listing is positioned alongside cheaper Humira biosimilars from Pfizer and Amgen. According to reporting, AbbVie’s participation includes an agreement intended to exempt the products from tariffs and future price mandates. The program is described as applicable to uninsured or underinsured patients who do not have coverage through existing insurance plans. The move adds another layer to the U.S. pricing framework being rolled out through government purchasing and distribution channels, affecting how large commercial brands compete on net price and patient access.